{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T11:18:12Z","timestamp":1767093492422},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Reportedly, a high plasma concentration of lamotrigine plays a role in the development of lamotrigine-related rash. The relationship between plasma concentrations of lamotrigine at week 2 and the lamotrigine-related rash was prospectively studied in 84 patients (22 males and 62 females) with treatment-resistant depressive disorder during an 8-week treatment of lamotrigine augmentation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eighty-four depressed patients with an insufficient response to at least 3 psychotropics, including antidepressants, mood stabilizers, and atypical antipsychotics, were included. The diagnoses were major depressive disorder (n = 39), bipolar I disorder (n = 10), and bipolar II disorder (n = 35). The final doses of lamotrigine were 100 mg\/d for 57 subjects who were not taking valproate and 75 mg\/d for 27 subjects taking valproate. Blood sampling was performed at week 2. Lamotrigine plasma concentrations were measured using high-performance liquid chromatography. The development of lamotrigine-related rash was assessed during the 8-week treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Six females developed lamotrigine-related rash. The mean plasma lamotrigine concentrations at week 2 were significantly (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.009) higher in the rash group (4.81 \u00b1 1.23 \u03bcmol\/L) than in the nonrash group (3.35 \u00b1 1.39 \u03bcmol\/L). Receiver-operating characteristic analysis indicated that a plasma lamotrigine concentration of 4.38 \u03bcmol\/L or greater at week 2 was significantly (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001) predictive of lamotrigine-related rash. The proportion of patients with a lamotrigine concentration of 4.38 \u03bcmol\/L or greater was significantly divided by the cutoff point into the rash group and the nonrash group (5\/1 versus 13\/65, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study suggests that a high plasma lamotrigine concentration during week 2 is a risk factor for lamotrigine-related rash and a plasma lamotrigine concentration of 4.38 \u03bcmol\/L may be a considered a threshold for rash in treatment-resistant depressive disorder.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000733","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T13:44:53Z","timestamp":1580132693000},"page":"631-635","source":"Crossref","is-referenced-by-count":8,"title":["A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash"],"prefix":"10.1097","volume":"42","author":[{"given":"Takeshi","family":"Suzuki","sequence":"first","affiliation":[{"name":"Hospital Pharmacy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Mihara","sequence":"additional","affiliation":[{"name":"Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goyo","family":"Nagai","sequence":"additional","affiliation":[{"name":"Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.107.048504","article-title":"Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials","volume":"194","author":"Geddes","year":"2009","journal-title":"Br J Psychiatry."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/S1092852916000523","article-title":"Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials","volume":"21","author":"Solmi","year":"2016","journal-title":"CNS Spectr."},{"key":"R3-20230814","first-page":"187","article-title":"Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability","volume":"21","author":"Ivkovi\u0107","year":"2009","journal-title":"Psychiatr Danub."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5234\/cnpt.1.35","article-title":"Lamotrigine augmentation for the treatment-resistant mood disorder","volume":"1","author":"Kagawa","year":"2010","journal-title":"Clin Neuropsychopharmacol Ther."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4088\/JCP.09m05355gre","article-title":"A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression","volume":"72","author":"Barbee","year":"2011","journal-title":"J Clin Psychiatry."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000088","article-title":"Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder","volume":"36","author":"Kagawa","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/FTD.0000000000000279","article-title":"Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-resistant depressive disorder from plasma concentration at week 2","volume":"38","author":"Nakamura","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000489967","article-title":"A partial response at week 4 can predict subsequent outcome during lamotrigine augmentation therapy in treatment-resistant depressive disorder: a preliminary study","volume":"76","author":"Nagai","year":"2017","journal-title":"Neuropsychobiology."},{"key":"R9-20230814","first-page":"1037","article-title":"Factors influencing the incidence of lamotrigine-related skin rash","volume":"33","author":"Wong","year":"1999","journal-title":"Neurology."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","article-title":"Predictors of lamotrigine-associated rash","volume":"47","author":"Hirsch","year":"2006","journal-title":"Epilepsy."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1528-1157.1999.tb00807.x","article-title":"Lamotrigine-associated rash: risk\/benefit considerations in adults and children","volume":"40","author":"Guberman","year":"1999","journal-title":"Epilepsy."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4088\/JCP.v63n1110","article-title":"Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management","volume":"63","author":"Calabrese","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2710.2012.01351.x","article-title":"Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics","volume":"37","author":"Brzakovi\u0107","year":"2012","journal-title":"J Clin Pharm Ther."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.pnpbp.2009.06.010","article-title":"Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective naturalistic, open-label trial","volume":"33","author":"Wo","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data","volume":"43","author":"Hussein","year":"1997","journal-title":"Br J Clin Pharmacol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/DDDT.S154388","article-title":"Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines","volume":"12","author":"Reimers","year":"2018","journal-title":"Drug Des Devel Ther."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1528-1167.2007.01109.x","article-title":"Rash from antiepileptic drugs: influence by gender, age, and learning disability","volume":"48","author":"Alvestand","year":"2007","journal-title":"Epilepsy."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.seizure.2018.06.024","article-title":"Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis","volume":"60","author":"Deng","year":"2018","journal-title":"Seizure."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:25:37Z","timestamp":1692051937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000733","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}